Amphetamine

Brands

DEA Class;  Rx

Common Brand Names; Adzenys XR-ODT, Dyanavel XR, Evekeo, Adzenys ER, Evekeo ODT

  • Stimulants; 
  • ADHD Agents

Sympathomimetic amine; a racemic mixture of L-amphetamine and D-amphetamine
Used for attention-deficit hyperactivity disorder (ADHD) and narcolepsy
Used as an anorectic agent in the short-term (8 to 12 weeks) exogenous treatment of obesity; abuse and addiction potential; not generally recommended by guidelines due to lack of longer-term health benefits

For the treatment of narcolepsy.
For the treatment of attention-deficit hyperactivity disorder (ADHD).
For the short-term (i.e., 8 to 12 weeks) treatment of exogenous obesity.

Advanced arteriosclerosis, symptomatic cardiovascular disease, or moderate-to-severe hypertension

In patients known to be hypersensitive to amphetamine, or other components

Patients with a history of drug abuse

During or within 14 days following the administration of MAOIs (hypertensive crises may result)

  • Decreased appetite (28%)
  • Infections (22%)
  • Abdominal pain (15%)
  • Irritability (14%)
  • Headache (13%)
  • Appetite loss (22-36%)
  • Dry mouth (1.6-35%)
  • Headache (1.6-26%)
  • Insomnia (5.2-17%)
  • Abdominal pain (11-14%)
  • Insomnia (10%)
  • Fatigue (10%)
  • Affect lability, includes mood swings (9%)
  • Tachycardia (9%)
  • Nausea (6%)
  • Vomiting (6%)
  • Dry mouth (6%)
  • Decreased appetite (4%)
  • Insomnia (4%)
  • Abdominal pain (3%)
  • Affect lability (3%)
  • Injury (3%)
  • Epistaxis (3.8%)
  • Rhinitis allergic (3.8%)
  • Upper abdominal pain (3.8%

Sudden death reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems

May cause a modest increase in average blood pressure (~2-4 mmHg) and heart rate (~3-6 bpm); caution with hypertension and other cardiovascular conditions

May exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder CNS stimulants may induce a mixed or manic episode in patients with bipolar disorder; before initiating treatment, screen for risk factors for developing a manic episode (eg, comorbid or has a history of depressive symptoms or a family history of suicide, bipolar disorder, and depression)

Treatment emergent psychotic or manic symptoms (eg, hallucinations, delusional thinking, mania) in children and adolescents without a prior history of psychotic illness or mania can be caused by stimulants at usual doses

Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD; monitor for the worsening of aggressive behavior or hostility

Monitor childhood growth during treatment; patients who are not growing or gaining height or weight as expected may need to interrupt their treatment

May lower seizure threshold in patients with prior history of seizures

Stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon

Pregnancy exposure registry monitors pregnancy outcomes in women exposed to amphetamines during pregnancy

Based on limited published case reports, amphetamine (d- or d1) is present in human milk at relative infant doses of 2-13.8% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.9and 7.5

Adults

12.5 mg/day PO (Adzenys XR products); 20 mg/day PO (Dyanavel XR); 60 mg/day PO (immediate-release products).

Geriatric

12.5 mg/day PO (Adzenys XR products); 60 mg/day PO (immediate-release products).

Adolescents

12.5 mg/day PO (Adzenys XR products); 20 mg/day PO (Dyanavel XR); 40 mg/day PO (immediate-release products).

Children

6 to 12 years: 18.8 mg/day PO (Adzenys XR products); 20 mg/day PO (Dyanavel XR); 40 mg/day PO (immediate-release products).
3 to 5 years: 40 mg/day PO for immediate-release products; safety and efficacy have not been established for extended-release formulations.
1 to 2 years: Safety and efficacy have not been established.

Infants

Safety and efficacy have not been established.

Neonates

Safety and efficacy have not been established.

Amphetamine sulfate

tablet (Evekeo): Schedule II

  • 5mg
  • 10mg

extended-release oral tablets (Dyanavel XR): Schedule II

  • 5mg
  • 10mg
  • 15mg
  • 20mg

extended-release oral suspension (Dyanavel XR): Schedule II

  • 2.5mg/mL

extended-release oral disintegrating tablet (Adzenys XR-ODT): Schedule II

  • 3.1mg
  • 6.3mg
  • 9.4mg
  • 12.5mg
  • 15.7mg
  • 18.8mg

extended-release oral suspension (Adzenys ER): Schedule II

  • 1.25 mg/mL
Drugs Generic
Tags

About the Author

postblaze

You may also like these

0